Association of non-alcoholic fatty liver disease with gastroesophageal reflux disease in patients with inflammatory bowel diseases
DOI: 10.32364/2587-6821-2021-5-6-373-376
Ya.A. Krasner, M.F. Osipenko, E.A. Bikbulatova, S.I. Kholin
Novosibirsk State Medical University, Novosibirsk, Russian Federation
Background: to date, the question of possible association between non-alcoholic fatty liver disease (NAFLD) and gastroesophageal reflux disease (GERD) is being considered. This association may be due to common risk factors for these two conditions, for example, obesity. However, several study results suggest the role of pro-inflammatory cytokines in the pathogenesis of NAFLD and GERD.
Of great interest is the study of these syndromes association in a group of patients with diseases accompanied by a systemic inflammatory process.
Aim: study of the association of NAFLD and GERD in a group of patients with inflammatory bowel diseases (IBD) without obesity and other metabolic risk factors.
Patients and Methods: the study involved 58 patients with a diagnosis of IBD. The study did not include patients with overweight, obesity and other metabolic risk factors. The presence of GERD was assessed based on survey data, the GERD-Q questionnaire and the results of an endoscopy.
Results and Discussion: the presence of GERD was associated with the presence of NAFLD in the studied group of patients (odds ratio (OR)=5.17; 95% confidence interval (CI) 1.46–18.28). There were no statistically significant differences in body mass index (BMI) between the groups of patients with NAFLD and without NAFLD (21.05 kg/m2 vs. 20.04 kg/m2, respectively, p=0.419). There was no statistically significant association of NAFLD with the use of systemic glucocorticosteroids in the anamnesis (OR=1.11; 95% CI 0.3–4.05), the presence of episodes of weight loss in the anamnesis (OR=0.48; 95% CI 0.11–2.11).
Conclusion: in patients with IBD, NAFLD is associated with the presence of GERD, regardless of BMI, the presence of carbohydrate metabolism disorders, as well as a history of weight loss episodes.
Keywords: gastroesophageal reflux disease, fatty liver disease, inflammatory bowel diseases.
For citation: Krasner Ya.A., Osipenko M.F., Bikbulatova E.A., Kholin S.I. Association of non-alcoholic fatty liver disease with gastroesophageal reflux disease in patients with inflammatory bowel diseases. Russian Medical Inquiry. 2021;5(6):373–376 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-373-376.
About the authors:
Yakov A. Krasner — C. Sc. (Med.), Assistant Professor of the Department of Propaedeutics of Internal Diseases of the Medical Faculty, Novosibirsk State Medical University; 52, Krasnyi Ave, Novosibirsk, 620091, Russian Federation; ORCID iD 0000-0003-0091-2299.
Maria F. Osipenko — Dr. Sc. (Med.), Professor, Head of the Department of Propaedeutics of Internal Diseases of the Medical Faculty, Novosibirsk State Medical University; 52, Krasnyi Ave, Novosibirsk, 620091, Russian Federation; ORCID iD 0000-0002-5156-2842.
Elena A. Bikbulatova — C. Sc. (Med.), Associate Professor of the Department of Propaedeutics of Internal Diseases of the Medical Faculty, Novosibirsk State Medical University; 52, Krasnyi Ave, Novosibirsk, 620091, Russian Federation; ORCID iD 0000-0001-7912-0758.
Sergei I. Kholin — C. Sc. (Med.), Associate Professor of the Department of Propaedeutics of Internal Diseases of the Medical Faculty, Novosibirsk State Medical University; 52, Krasnyi Ave, Novosibirsk, 620091, Russian Federation; ORCID iD 0000-0002-3016-2217.
Contact information: Yakov A. Krasner, e-mail: yakov.krasner@yandex.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 12.07.2021.
Revised 04.08.2021.
Accepted 27.08.2021.
2. Livzan M.A., Gaus O.V., Nikolaev N.A., Krolevec T.S. NAFLD: comorbid and associated diseases. Jeksperimental’naja i klinicheskaja gastrojenterologija. 2019;10(170):57–65 (in Russ.). DOI: 10.31146/1682-8658-ecg-170-10-57-65.
3. Xue J., Xin H., Ren N. et al. Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: A systematic review and meta-analysis 2019. Eur J Clin Invest. 2019;49(9):e13158. DOI: 10.1111/eci.13158.
4. Tan J.J., Li L., Huang X. et al. Associations between gastro-oesophageal reflux disease and a range of diseases: an umbrella review of systematic reviews and meta-analyses. BMJ Open. 2020;10(12):e038450. DOI: 10.1136/bmjopen-2020-038450.
5. Wijarnpreecha K., Panjawatanan P., Thongprayoon C. et al. Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis. Saudi J Gastroenterol. 2017;23(6):311–317. DOI: 10.4103/sjg.SJG_161_17.
6. Min Y.W., KimY., Gwak G.Y. et al. Non-alcoholic fatty liver disease and the development of reflux esophagitis: A cohort study. J Gastroenterol Hepatol. 2018;33(5):1053–1058. DOI: 10.1111/jgh.14042.
7. Yang H.J., Chang Y., Park S.K. et al. Nonalcoholic fatty liver disease is associated with increased risk of reflux esophagitis. Dig Dis Sci. 2017;62(12):3605–3613. DOI: 10.1007/s10620-017-4805-6.
8. Bang K.B., Shin J.E., Shin H.D. et al. Non-obese non-alcoholic fatty liver disease is associted with erosive esophagitis. Gastroenterology. 2018;154(6):241. DOI: 10.1016/S0016-5085(18)31184-3.
9. Catanzaro R., Calabrese F., Occhipinti S. et al. Nonalcoholic fatty liver disease increases risk for gastroesophageal reflux symptoms Dig Dis Sci. 2014;59(8):1939–1945. DOI: 10.1007/s10620-014-3113-7.
10. Rieder F., Biancani P., Harnett K. et al. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):571–581. DOI: 10.1152/ajpgi.00454.2009.
11. Cheng H.H., Chang C.S., Wang H.J., Wang W.C. Interleukin-1beta and -10 polymorphisms influence erosive reflux esophagitis and gastritis in Taiwanese patients. J Gastroenterol Hepatol. 2010;25(8):1443–1451. DOI: 10.1111/j.1440-1746.2010.06310.x.
12. Picos A., Vulturar R., Picos A. et al. Interleukin-1A and interleukin-1B gene polymorphisms in gastroesophageal reflux disease. Exp Ther Med. 2020;20(4):3394–3398. DOI: 10.3892/etm.2020.9030.
13. Niederreiter L., Tilg H. Cytokines and fatty liver diseases. Liver Research. 2018;2(1):14–20. DOI: 10.1016/j.livres.2018.03.003.
14. Ivashkin V.T., Shelygin Ju.A., Halif I.L. et al. Ulcerative colitis clinical practice guidlines of Russian gastroenterologists’ association and Association of coloproctologists of Russia. Koloproktologija. 2017;1:6–30 (in Russ.).
15. Ivashkin V.T., Shelygin Ju.A., Halif I.L. et al. Crohn disease clinical practice guidlines of Russian gastroenterologists’ association and Association of coloproctologists of Russia, Koloproktologija. 2017;2:7–29 (in Russ.).
16. Castéra L., Vergniol J., Foucher J. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–350. DOI: 10.1053/j.gastro.2004.11.018.
17. Vallet-Pichard A., Mallet V., Nalpas B. et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–36. DOI: 10.1002/hep.21669.
18. Livzan M.A., Ahmedov V.A., Krolevec T.S. et al. The informative value of foninvasive liver fibrosis markers in NAFLD patients. Terapevticheskij arhiv. 2016;88(12):62–68 (in Russ.). DOI. 10.17116/terarkh2016881262–68.
19. Jones R., Junghard O., Dent J. et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2009;30(10):1030–1038. DOI: 10.1111/j.1365-2036.2009.04142.x.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
